Investment Rating - The investment rating for the company is "Outperform the Market" [2] Core Views - The company is expected to achieve significant revenue growth driven by volume increases in both adult and children's footwear and apparel, with a projected revenue increase of 19.6% to 10.074 billion yuan in 2024 [6] - The company has shown a stable profit level, with net profit expected to grow by 19.5% to 1.149 billion yuan in 2024, maintaining a net profit margin of 11.4% [6] - The company is focusing on expanding its store network and optimizing its channel structure, with a particular emphasis on the new "super product" stores aimed at capturing market opportunities [6] Financial Summary - Revenue projections for the company are as follows: - 2023: 8.423 billion yuan - 2024: 10.074 billion yuan - 2025E: 11.486 billion yuan - 2026E: 12.914 billion yuan - 2027E: 14.355 billion yuan - Year-over-year revenue growth rates are projected at 21.0% for 2023, 19.6% for 2024, 14.0% for 2025, 12.4% for 2026, and 11.2% for 2027 [5] - Net profit projections are as follows: - 2023: 961 million yuan - 2024: 1.149 billion yuan - 2025E: 1.292 billion yuan - 2026E: 1.501 billion yuan - 2027E: 1.672 billion yuan - Year-over-year net profit growth rates are projected at 28.7% for 2023, 19.5% for 2024, 12.5% for 2025, 16.2% for 2026, and 11.3% for 2027 [5] - The company plans to pay a final dividend of 0.10 HKD per share, with a total payout ratio of 45%, an increase of 4.8 percentage points year-over-year [6] Market Performance - The company's stock closed at 4.52 HKD on March 24, 2025, with a 52-week price range of 3.02-4.98 HKD [2] - The company has shown an absolute price increase of 13.3% over the past month and a relative increase of 10.9% compared to the Hang Seng Index [4] Strategic Initiatives - The company is expanding its online sales channels, with e-commerce revenue expected to grow by 12.2% in 2024, while also making progress in overseas market development [6] - The introduction of new product lines and the optimization of the store network are expected to enhance store efficiency significantly [6]

Investment Rating - The report maintains a "Buy" rating for the company with a target price not specified [4] Core Insights - The company achieved a revenue of 1.102 billion, representing a year-on-year increase of 125.2%, and a net profit of 192 million, up 114%, indicating strong performance in its core business and significant results from its quality transformation [1] - In 2024, the company made a historic breakthrough in the quality education sector, generating 710 million in revenue, which accounted for 64.7% of total revenue and showed a remarkable growth of 411.7% year-on-year [1] - The tutoring project revenue grew steadily by 25.2% to 181 million, while the full-time repeat business revenue slightly increased by 1% to 210 million, with an improved market share [1] - The company reported a gross profit margin of 46.3% and a bank deposit balance of 1.12 billion, which increased by 124% year-on-year, indicating strong financial health and sustained demand for quality education services [1] Summary by Sections AI Technology Empowerment - The company is advancing its "All in AI" strategy, upgrading its "Whale Education System" with AI capabilities to create personalized learning paths and improve teaching efficiency [2] - The intelligent essay correction system has been successfully implemented, significantly enhancing teachers' grading efficiency [2] - The AI assistant has been launched to improve lesson preparation efficiency and teaching content quality, allowing teachers to focus more on classroom presentation and student well-being [2] Expansion and AI Application - The company plans to introduce a personalized question recommendation feature based on AI data analysis, helping students find the best learning paths [3] - The AI department will accelerate the deployment of AI across various business and management processes, developing customized AI products for teachers to enhance teaching quality [3] - The company will increase resource investment in Shenzhen and Foshan, including new outlets, recruiting excellent teachers, and improving teaching facilities to enhance brand recognition and market competitiveness [3] Financial Forecast Adjustments - Based on the 2024 performance, the company adjusted its profit forecasts for 2025-2027, expecting revenues of 2.11 billion, 2.68 billion, and 3.40 billion respectively, with adjusted net profits of 314 million, 397 million, and 506 million [4] - The earnings per share (EPS) are projected to be 0.37, 0.47, and 0.60 for the years 2025, 2026, and 2027 respectively [4]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price not specified [4]. Core Insights - The company achieved a revenue of 1.102 billion, representing a year-on-year increase of 125.2%, and a net profit of 192 million, up 114%, indicating strong performance in its core business and significant results from its quality transformation [1]. - In 2024, the company made a historic breakthrough in the quality education sector, generating 710 million in revenue, which accounted for 64.7% of total revenue and showed a remarkable growth of 411.7% year-on-year [1]. - The company is advancing its "All in AI" strategy, enhancing its educational systems with AI technology to improve teaching efficiency and personalize learning paths for students [2][3]. Financial Performance - The company reported a gross profit margin of 46.3% and a bank deposit balance of 1.12 billion, which is a 124% increase year-on-year. Contract liabilities reached 600 million, up 184% year-on-year, reflecting strong demand for quality education services [1]. - The adjusted profit forecasts for 2025-2027 are 3.14 billion, 3.97 billion, and 5.06 billion respectively, with earnings per share (EPS) projected at 0.37, 0.47, and 0.6 [4].

Investment Rating - The investment rating for Geely Automobile is "Buy" (maintained) [1] Core Views - The Q4 performance of Geely Automobile met expectations, with total revenue of 72.51 billion yuan, representing a year-on-year increase of 29.7% and a quarter-on-quarter increase of 20.1%. The net profit attributable to shareholders was 3.579 billion yuan, with year-on-year growth of 45.4% and quarter-on-quarter growth of 45.8% [8] - The company aims to achieve a sales target of 2.71 million vehicles in 2025, with 1.5 million of those being new energy vehicles. The company is actively promoting its "Smart Geely 2025" strategy [8] Summary by Sections Financial Performance - In Q4, Geely's total sales reached 687,000 units, with year-on-year growth of 30.3% and quarter-on-quarter growth of 28.6%. The average selling price for Geely and Zeekr vehicles was 121,000 yuan, showing a slight decrease [8] - The gross margin for Q4 was 17.3%, an increase of 1.0 percentage points year-on-year, driven by improved profitability from high-margin oil vehicles and enhanced profitability from new energy products [8] Earnings Forecast - The forecast for total revenue is as follows: - 2023: 179.846 billion yuan - 2024: 240.194 billion yuan (33.56% YoY) - 2025: 344.279 billion yuan (43.33% YoY) - 2026: 397.884 billion yuan (15.57% YoY) - 2027: 475.326 billion yuan (19.46% YoY) [1] - The net profit attributable to shareholders is projected to be: - 2023: 5.308 billion yuan - 2024: 16.632 billion yuan (213.32% YoY) - 2025: 14.153 billion yuan (-14.91% YoY) - 2026: 19.599 billion yuan (38.48% YoY) - 2027: 27.060 billion yuan (38.07% YoY) [1] Valuation Metrics - The latest diluted EPS is projected as follows: - 2023: 0.53 yuan - 2024: 1.65 yuan - 2025: 1.40 yuan - 2026: 1.95 yuan - 2027: 2.69 yuan [1] - The P/E ratios are projected as follows: - 2024: 9.48 - 2025: 11.14 - 2026: 8.05 - 2027: 5.83 [1]

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 23.82 [8][9]. Core Insights - The company reported a revenue of RMB 12.261 billion for 2024, representing a year-on-year growth of 21.3%, and a net profit of RMB 4.372 billion, up 33.4% year-on-year. The revenue from innovative drugs reached RMB 9.477 billion, growing 38.1% year-on-year, and accounting for 74% of total revenue, which aligns with expectations [1][2]. - The growth in revenue is driven by strong performance in oncology and anti-infection segments, with revenues of RMB 8.122 billion and RMB 1.464 billion respectively, reflecting increases of 31.7% and 15.4% year-on-year. The gross margin improved to 91%, while the R&D expense ratio increased to 22%, indicating ongoing investment in innovation [2][3]. - The company has seven innovative drugs and nine indications included in the national medical insurance catalog as of 2024, with over 40 new molecular entities in more than 60 clinical trials. The company completed three license-in agreements in 2024, generating R&D expenses of RMB 247 million [3][4]. Summary by Sections Financial Performance - For 2024, the company achieved revenues of RMB 12.261 billion, with a year-on-year growth of 21.35%. The net profit for the same year was RMB 4.372 billion, reflecting a growth of 33.39% [7][19]. - The projected net profits for 2025 and 2026 are RMB 4.400 billion and RMB 4.179 billion respectively, with an expected EPS of RMB 0.74 for 2025 [5][19]. Research and Development - The company has a robust pipeline with 40 new molecular entities and over 60 clinical trials ongoing. Key drugs like Amatinib are expected to generate significant sales, projected to reach RMB 6 billion by 2025 [4][5]. - The company is actively expanding into autoimmune diseases and has multiple assets in development for skin diseases and kidney diseases [4][5]. Valuation - The company is valued at HKD 1,414 billion, with the innovative drug segment valued at HKD 1,378 billion and the generic drug segment at HKD 36 billion. The target price reflects an increase from the previous valuation of HKD 22.28 [5][9].

奥维云网数据显示，24Q4 线上/线下 KA 电视机行业零售量分别同比 +4.74%/+3.09%，公司份额重获增长，TCL 及雷鸟品牌市占率同比提升 3.42/4.07 个百分点。我们认为 2025 年换新政策将继续催化中高端需求， 25 年 1-2 月公司零售量份额继续强化（线上 TCL 同比+ 0.85pct、雷鸟 +3.62pct；线下 TCL+3.54pct），可以继续期待公司份额提升。同时产品结 构升级明显、盈利优化可期，公司 1-2 月 TCL 线上均价同比+12.9%。 港股通 24 年净利超预期，看好电视结构升级 | 华泰研究 | | | 年报点评 | | --- | --- | --- | --- | | 2025 年 | 3 月 | 23 日│中国香港 | 视听器材 | 证券研究报告 公司公布 2024 年业绩：收入 993.22 亿港元，同比+25.7%；归母净利润 17.59 亿港元，同比+136.6%；经调整归母净利 16.06 亿港元，+100.1%。公司着 力经营效率提升，费用率优化明显，24 年业绩大幅好于我们预期（预期归 母净利 12.3 亿元）。受益于以旧换新政策红利及显 ...

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 7.01 [7][8]. Core Views - The company reported a revenue of RMB 852 million for 2024, representing a year-on-year increase of 49.4%, and an adjusted net profit of RMB 176 million, up 62.7% year-on-year. Both revenue and profit align with the performance forecast [1][2]. - The company plans to restart dividend payments in 2024, with an expected gradual increase in the dividend payout ratio over the next three years, targeting approximately 25% in 2024 [1]. - The company is actively seizing opportunities in the Shenzhen market due to improved regional dynamics, continuously expanding its market share [2][3]. Summary by Sections Financial Performance - For 2024, the company achieved a revenue of RMB 852 million, a 49.4% increase year-on-year, and an adjusted net profit of RMB 176 million, a 62.7% increase year-on-year. The gross profit and adjusted net profit for 2024 were RMB 333 million and RMB 176 million, respectively, exceeding pre-"double reduction" levels [1][2]. - The company’s quality education revenue reached RMB 767 million, up 47.79% year-on-year, while tutoring course revenue grew 65.22% to RMB 86 million, driven mainly by an increase in class hours [2]. Market Expansion - The company has resumed its expansion in the Guangzhou market, opening nine new campuses by the end of 2024, with overall enrollment exceeding expectations. The focus will be on revenue and market share growth in the coming two to three years [3][4]. - The company plans to enhance its teaching staff by increasing the proportion of teachers with top-tier academic qualifications to over 85% and will strengthen its middle-tier capabilities to support business expansion [4]. Profit Forecast and Valuation - The profit forecast for 2025-2027 is adjusted slightly, with expected adjusted net profits of RMB 244 million, RMB 329 million, and RMB 424 million, reflecting increases of 5% and 7% for 2025 and 2026, respectively [5][12]. - The target price of HKD 7.01 is based on a 15x PE ratio for 2025, considering the company's relatively lower liquidity compared to comparable companies listed in the US and A-shares [5][12].

Investment Rating - The report maintains a "Buy" investment rating for the company [1][8] Core Views - The company reported a slight revenue growth of 0.05% and a net profit increase of 23.12% for 2024, with revenues and net profits reaching 13.521 billion and 1.637 billion respectively [4] - The gross margin improved to 47.31%, up by 2.66 percentage points, attributed to increased production from self-owned factories and reduced raw material costs [4] - The beverage business saw significant growth, with revenue increasing by 30.80%, while packaged drinking water revenue declined by 2.59% [5] - The company is actively expanding its national presence and increasing the proportion of self-owned production, aiming for over 60% self-owned capacity by the end of the current five-year plan [6] Financial Performance Summary - For 2024, the company expects revenues of 13.521 billion, with projected growth rates of 6.8%, 7.5%, and 7.7% for the years 2025 to 2027 [10] - The earnings per share (EPS) are projected to be 0.84, 0.97, and 1.12 for 2025, 2026, and 2027 respectively, with corresponding price-to-earnings (P/E) ratios of 16, 14, and 12 [8][10] - The company’s return on equity (ROE) is expected to remain stable around 14.5% to 15.1% over the forecast period [10] Market Position and Strategy - The company is focusing on enhancing its distribution channels, with a 15% increase in retail coverage and over 20% growth in commercial refrigeration units [6] - New product launches and flavor innovations are driving the beverage segment, with a 122% increase in sales volume for a key product line [5][8] - The company is also investing in expanding production capacity, adding 22 new production lines, which includes 14 high-speed water lines and 3 sterile beverage lines [6]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company achieved a record revenue of over 70 billion RMB, focusing on a multi-brand strategy for stable long-term growth [5][7] - The company's revenue for 2024 reached 70.826 billion RMB, representing a year-on-year growth of 13.6%, with a gross profit of 44.032 billion RMB, up 12.8% year-on-year [7] - The net profit attributable to shareholders for 2024 was 15.596 billion RMB, a significant increase of 52.4% year-on-year [7] - The multi-brand strategy continues to support stable growth, with the main brand achieving a revenue of 33.52 billion RMB, up 10.6% year-on-year [7] - The online and overseas channels are expected to continue driving growth, with online revenue increasing by 21.8% year-on-year [7] Financial Forecasts - Revenue projections for the company are as follows: 62.661 billion RMB in 2023, 70.826 billion RMB in 2024, 78.945 billion RMB in 2025, 87.796 billion RMB in 2026, and 96.557 billion RMB in 2027 [6] - The net profit attributable to shareholders is forecasted to be 13.500 billion RMB in 2025, 15.561 billion RMB in 2026, and 17.150 billion RMB in 2027, with a year-on-year growth of -13.44%, 15.27%, and 10.21% respectively [6][7] - The company's return on equity (ROE) is projected to be 25.27% in 2024, decreasing to 17.93% in 2025, and further to 17.12% in 2026 [6]

Investment Rating - The report maintains a "Buy" rating for China Biologic Products (1177 HK) with a target price of HKD 4.80, indicating a potential upside of 29.8% from the current price of HKD 3.70 [1][2][6]. Core Insights - The adjusted net profit for 2024 exceeded expectations, with revenue growth projected at 10.2% year-on-year to RMB 28.866 billion, aligning with market expectations and the company's previous guidance for double-digit growth. The contribution from new products has risen to over 40%, with expectations to launch over 10 new products in the next 2-3 years, driving continued double-digit revenue growth despite a challenging environment of centralized procurement and healthcare cost control [2][6][13]. - The report highlights that the gross profit margin improved by 0.5 percentage points to 81.5%, driven by factors such as group procurement and increased capacity utilization. R&D expenses are expected to exceed RMB 5 billion for the first time, with a slight increase in the expense ratio to 17.6% [6][13]. - The company is entering a phase of significant product launches, with six innovative products expected to be launched in 2024, including four Class 1 new drugs. This is anticipated to increase the contribution of new products to total revenue to 60% by 2025-2027 [6][13]. Financial Forecast Changes - Revenue forecasts for 2025E and 2026E have been adjusted downwards by 2%, with new projections of USD 32.788 billion and USD 37.034 billion respectively. The adjusted net profit for 2025E is projected at RMB 2.971 billion, reflecting a decrease from previous estimates [5][6][13]. - The report anticipates a gradual improvement in gross margins as product transitions are completed, with operational expense ratios expected to stabilize or decrease [6][13]. Stock Performance - The stock has shown a year-to-date increase of 15.63%, with a 52-week high of HKD 4.15 and a low of HKD 2.34. The average daily trading volume is approximately 108.74 million shares [4][6].